ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

Leukemia

Volumn 28, Issue 10, 2014, Pages 2090-2092

  Falchi, L ^a   Mehrotra, M ^a   Newberry, K J ^a   Lyle, L M ^a   Lu, G ^a   Patel, K P ^a   Luthra, R ^a   Popat, U ^a   Verstovsek, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLT3 LIGAND; FLUDARABINE; SORAFENIB; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR ETV6; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NICOTINAMIDE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER THERAPY; CASE REPORT; EOSINOPHILIA; EOSINOPHILIA ASSOCIATED MYELOPROLIFERATIVE NEOPLASM; FEMALE; FUSION GENE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIMODALITY CANCER THERAPY; MYELOPROLIFERATIVE NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CYTOGENETICS; GENETICS; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDERS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; CYTOGENETICS; EOSINOPHILIA; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; MUTATION; MYELOPROLIFERATIVE DISORDERS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84921812914     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.168     Document Type: Letter

References (11)

1. Bain B, Gilliland D, Horny H-P, Vardiman J. Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, or FGFR1. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, pp 68-73
2. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res 2012; 36: 945-961
3. Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006; 20: 1414-1421
4. Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMSlike tyrosine kinase 3. Blood 2011; 118: 2239-2242
5. Chonabayashi K, Hishizawa M, Matsui M, Kondo T, Ohno T, Ishikawa T et al. Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. Ann Hematol 2013; 93: 535-537
6. Jaso JM, Yin CC, Lu VW, Zhao M, Abruzzo LV, You MJ et al. B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol 2013
7. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka lR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-1152
8. Rosnet O, Mattei M-G, Marchetto S, Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991; 9: 380-385
9. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665
10. Vu HA, Xinh PT, Kano Y, Tokunaga K, Sato Y. The juxtamembrane domain in ETV6/ FLT3 is critical for PIM-1 up-regulation and cell proliferation. Biochem Biophys Res Commun. 2009; 383: 308-313
11. Chonabayashi K, Hishizawa M, Kawamata S, Nagai Y, Ohno T, Ishikawa T et al. Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3. Leukemia 2013; 27: 1433-1436.